Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies

Table 4 Treatment-related AEs occurring in > 1 patient in AFM11-102

Adverse event	Cohort 1 (n = 2)	Cohort 2 (n = 1)	Cohort 3 (n = 3)	Cohort 4 (n = 3)	Cohort 5 (n = 5)	Cohort 6 (n = 3)	Overall n = 17
Patients with any TEAE related to study treatment	2	1	1	3	4	2	13
Pyrexia	0	1	1	2	2	1	7
Alanine aminotransferase increased	0	0	0	0	2	1	3
Aspartate aminotransferase increased	0	0	0	0	2	1	3
Tremor	0	0	0	1	1	1	3
Bone pain	0	0	0	0	2	0	2
Febrile neutropenia	1	0	0	1	0	0	2
Headache	0	0	1	0	0	1	2
Myalgia	0	0	1	0	1	0	2
Neutropenia	0	0	0	1	1	0	2

AE adverse event; TEAE treatment-emergent adverse event
Dose of AFM11 by cohort (cycle 1 week 1, cycle 1 week 2 onward) was as follows: cohort 1, 0.0007 μg/kg/week, 0.002 μg/kg/week; cohort 2, 0.002 μg/kg/week, 0.006 μg/kg/week; cohort 3, 0.007 μg/kg/week, 0.02 μg/kg/week; cohort 4, 0.02 μg/kg/week, 0.06 μg/kg/week; cohort 5, 0.06 μg/kg/week, 0.18 μg/kg/week; cohort 6, 0.13 μg/kg/week, 0.4 μg/kg/week

ISSN: 1745-6215